# Causal links between mitophagy and Alzheimer's disease: a Mendelian randomization study

Weijian Zhang 1,2¶, Wenjia Chen<sup>2&</sup>, Zhendong Guo<sup>1&</sup>, Hui Li<sup>2,3</sup>¶\*

lihuitcm@126.com (H. Li).

- 1 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China
- 2 Research Group of Standardization for Chinese medicine, Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangzhou, P.R. China
- 3 State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangzhou, P.R. China
- \* Corresponding author. Address: Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), No. 111 Dade Rd, Yuexiu District, Guangzhou, Guangdong Province, China. Tel: +86-20-81887233. E-mail:

Background

Emerging evidence highlights the dysregulation of mitophagy, the process of clearing damaged mitochondria, as a potential contributor to Alzheimer's disease (AD) pathology. However, the precise mechanisms linking mitophagy to AD remain poorly understood. This study utilized summary-data-based Mendelian Randomization (SMR) combined with multi-omics data to explore the causal relationships between them, and to uncover potential epigenetic mechanisms of gene regulation.

Methods

Mitophagy-related genes were identified through the integration of three databases, and transcriptomic data of AD patients were obtained from the Gene Expression Omnibus (GEO) database. A meta-analysis was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in AD. Through SMR tools, genome-wide association study (GWAS) summary data of AD from the GWAS Catalog (n=487,511) were separately integrated with expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) from blood and brain tissues to identify potentially causal genes and methylation sites. The findings from primary analysis were validated with data from the UK Biobank (n=301,478).

**Results** 

In total, 111 mitophagy-related genes were found to be differentially expressed in AD. The three-step SMR analysis identified two genes, PARL and BCL2L1, from blood tissues and three genes, ATG13, TOMM22, and SPATA33, from brain tissues as causal candidate genes associated with AD. The analysis pinpointed the possible epigenetic mechanisms, where specific methylation sites regulate the expression of these genes, potentially contributing to

2

their association with AD. All findings were successfully replicated in UK Biobank cohorts.

#### Conclusions

The study emphasized the putatively causal relationships of mitophagy-related gene with AD.

These underlying pathogenic mechanisms could pave the way for new approaches in early detection and therapeutic intervention for AD.

**Keywords** Mitophagy, Alzheimer's disease, multi-omics, Mendelian randomization

### Background

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Alzheimer's disease (AD), the leading cause of dementia in older adults worldwide, is a progressive, age-related neurodegenerative disorder characterized by memory impairment, cognitive decline, personality changes, and language disorders [1]. Its major pathological features include amyloid beta (Aβ) plaques, neurofibrillary tangles of hyperphosphorylated tau (p-tau), and neuroinflammation. Although the etiology of AD remains poorly understood, it is generally believed that the multifaceted interplay of genetic variation, environmental factors, and lifestyle underpins the pathogenesis of AD, especially in sporadic cases [2]. The brain is one of the most energy-demanding organs, and brain cells are particularly vulnerable to mitochondrial damage [3]. The homeostasis of both neurons and glial cells is heavily dependent on the normal function of mitophagy, the central component of mitochondrial quality control [4]. Mitophagy refers to the selective degradation of defective mitochondria via the autophagy pathway [5]. By removing dysfunctional mitochondria in neurons and supporting glial cells, mitophagy not only reduces cellular damage caused by reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) leakage, but also enhances microglial phagocytosis of misfolded proteins like AB and tau in neurodegenerative diseases [6]. This process helps to attenuate neuroinflammation, primarily induced by the release of pro-inflammatory cytokines or ROS, and maintain cellular homeostasis in AD models, thereby preventing bioenergetic failure and cell death [7]. Mounting evidence implicates that mitophagy is significantly dysregulated in the brains of AD patients and AD models, which may be one of the underlying contributors to the manifestation and pathophysiology of the disease [8]. Altered expression levels of several

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

mitophagy-related proteins, such as PINK1, p62, and LC3, have been observed in postmortem human AD brains [9, 10]. Impaired mitophagy exacerbates oxidative damage and cellular energy depletion, leading to the aggregation of AB and p-tau proteins, which in turn disrupt the mitophagy mechanism itself [11]. PINK1/Parkin signaling, involving proteins such as PINK1, Parkin, and p62, is an important pathway regulating mitophagy [12]. PINK1-deficient mAPP mice exhibited earlier and increased Aβ accumulation, mitochondrial dysfunction, and cognitive impairment [13], while knocking out the p62 gene accelerated p-tau aggregation and neurodegeneration in PS19 mice [14]. Experimental evidence showed that upregulation of mitophagy-related proteins by genetic or pharmacological intervention could potentially increase mitophagy flux and ameliorate cognitive deficits in AD models [11, 13, 15]. Epigenetic modifications, particularly aberrant DNA methylation (DNAm) at CpG sites introduced by environmental factors, also play a vital role in AD development [16]. Both global and site-specific DNA hypomethylation have been found in post-mortem AD human brains and AD animal models [17, 18]. DNA methylation status in specific gene promoter or enhancer regions can affect Aβ deposition and neurofibrillary tangle formation by altering gene expression [19]. For example, hypomethylation in the promoter of BACE1 or PSEN1, both integral to the AB production, increases AB aggregates in AD mice by upregulating the expression of these genes [20, 21]. Multiple genome-wide association studies (GWAS) in AD patients have successfully identified several genetic susceptibility loci related to mitochondrial function, including APOE, TOMM40, and CLU, especially in late-onset AD cases [22-24]. Furthermore, methylome-wide association

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

studies (MWAS) have also detected numerous AD-related DNA methylation marks, notably in genes such as APOE, MAPT, ANK1, and HOXA3 [25-27]. Despite these findings, which have expanded our knowledge of the genetic architecture and epigenetic mechanisms in AD, the associations identified from GWAS and MWAS may not be the direct genetic causes of the disease due to confounding effects from environmental and genetic factors [28, 29]. The specific role of mitophagy-related genes and their regulatory elements in AD remains elusive. Summary data-based Mendelian randomization (SMR) is a method that combines GWAS data with molecular trait data, such as expression quantitative trait loci (eQTL) and DNA methylation QTL (mQTL), with the objective of investigating putative causal relationships between the molecular signatures and diseases [30]. Given that AD is a progressive neurodegenerative disorder affecting the central nervous system [31], analyzing the putative effects of genetic variants on brain-expressed genes may yield more meaningful insights than blood-based analyses. Accordingly, we employed a three-step SMR approach, integrating AD GWAS summary statistics with eQTL/mQTL data from blood and brain tissues separately, to investigate gene expressions and DNAm sites potentially causally linked to AD. Furthermore, the replication analysis using data from UK Biobank datasets validated findings from the primary analysis to ensure the robustness and reliability of the discovery. Methods Study design The study design is illustrated in Figure 1. Initially, a meta-analysis of transcriptomic data was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

AD patients. Subsequently, the three-step SMR approach integrated AD GWAS summary statistics with eQTL/mQTL data of DEGs to identify potential causal relationships between these genes and AD. The SMR tests were conducted using eQTL and mQTL data from blood tissues, separately. Genes and methylation sites identified as significant in the primary analysis were then validated using data from UK Biobank. Fig 1. Flowchart of the study. AD, Alzheimer's disease; cis-eQTLs, cis-expression quantitative trait loci; cis-mQTL, cis-methylation quantitative trait loci; GWAS, Genome-wide association studies; SMR, summary-based Mendelian randomization; SNP, single nucleotide polymorphisms. Data resources Mitophagy-related genes were retrieved from the Gene Set Enrichment Analysis (GSEA), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology Resource (GO) using the search terms "mitophagy". Five microarray datasets for AD patients were gained from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) (S1 Table) [32-44]. In the primary analysis, GWAS summary statistics for AD from the GWAS Catalog were used, consisting of a total of 487,511 individuals, including 39,106 clinically diagnosed AD cases, 46,828 proxy cases, and 401,577 controls [45]. These data were obtained from a meta-analysis of AD GWAS datasets collected across 15 European countries, combining results from the European Alzheimer & Dementia Biobank (EADB) consortium and the UK Biobank. The data **GWAS** GCST90027158 can be accessed publicly via the Catalog (https://www.ebi.ac.uk/gwas/studies/GCST90027158).

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

For external validation, we utilized GWAS summary data from the UK Biobank, encompassing a total of 301,478 individuals, with 25,392 AD cases and 276,086 controls [45]. The proxy-AD cases were determined based on questionnaire data in which individuals were asked if their parents had a diagnosis of dementia. All individuals analyzed in both the primary analysis and validation stages were of European ancestry. Blood eQTL summary data of mitophagy-related genes were procured from eQTLGen, which contains statistics on blood gene expression from 31,684 individuals [46]. Blood mQTL data obtained through a meta-analysis implemented on two cohorts (n=1,980) [47]. Brain eQTL data were derived from BrainMeta v2 cis-eQTL summary data project (n= 2,865) [48], while the brain mQTL data were derived from the Brain-mMeta mQTL dataset (n = 1,160), generated through a meta-analysis that combined data from the studies by ROSMAP et al., Hannon et al., and Jaffe et al. [49]. This study focused on cis-eQTLs and cis-mQTLs, defined as single nucleotide polymorphisms (SNPs) located within a 1000 kb range upstream or downstream of the gene of interest. For comprehensive details about the data used in the study, please refer to Supporting information. Statistical analysis Identification of DEGs DEGs related to mitophagy between AD patients and healthy controls (HCs) were identified using linear regression models for each dataset, with adjustments for age, sex, and other relevant covariates to account for potential confounding factors. A meta-analysis with a fixedeffects model was then carried out using the R package *metafor* to integrate the DEGs from individual datasets and derive the final set of DEGs [50].

#### SMR for detecting putative causal relationship

SMR tools were specifically designed to assess whether genetic variants influence complex traits through intermediate molecular traits, such as gene expression, DNA methylation, or protein abundance [30]. The 1000 Genomes European reference was used to calculate linkage disequilibrium [51], while the heterogeneity of dependent instruments (HEIDI) tests were employed for the assessment of heterogeneity [30].

The SMR analysis was conducted three times respectively using molecular QTL data from blood and brain tissues, with SNPs serving as genetic instrument variables in all three steps: (1) blood or brain eQTLs as exposures, with AD as the outcome; (2) blood or brain mQTLs as exposures, with AD as the outcome; (3) significant findings from step 1 as exposures, and findings from step 2 as outcomes. The significant causal associations were identified in accordance with the following criteria: (1) passing all three-step SMR with the threshold of  $P_{SMR-multi} < 0.05$ ; (2) demonstrating genome-wide significance, with  $P < 1 \times 10^{-6}$  across all QTL datasets; and (3) displaying no significant heterogeneity ( $P_{PEDI} > 0.05$ ).

#### Results

#### DEGs associated with mitophagy

After removing duplicates, 167 unique mitophagy-related genes were collected from three databases (S2 Table). The recognition of DEGs was conducted on each of the five microarray datasets to contrast the expression levels of transcripts between AD patients (n=401) and HCs (n=388) (S1 Table). After the meta-analysis of results from these five datasets, 111 mitophagy-related genes were recognized as DEGs in AD (P < 0.05) (Fig 2 and S3 Table).

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Fig 2. Volcano Plot of differentially expressed genes (DEGs) related to mitophagy in AD. A meta-analysis of five microarray datasets was conducted to compare gene expression between AD patients and healthy controls. In volcano plot, the x-axis represents meta-analysis effect sizes, while the y-axis shows the  $-\log of meta p$  value, indicating statistical significance. Red dots highlight the 111 significant differentially expressed genes (DEGs), while black dots represent non-significant genes. The dashed line marks the significance threshold at p < 0.05. Integration of GWAS and mitophagy-related eQTL/mQTL data from blood and brain tissues As outlined previously, we sought to identify candidate causal genes for AD and elucidate the epigenetic mechanisms involved. Our three-step SMR analysis combined AD GWAS summary statistics from the GWAS Catalog with blood or brain cis-eQTLs/cis-mQTLs data of 111 mitophagy-related DEGs. Integrating blood eQTL data from the eQTLGen Consortium (n = 31,684) with AD GWAS summary data identified 5 mitophagy-related genes ( $P_{SMR-multi}$  < 0.05,  $P_{HEIDI}$  > 0.05) (S4 Table). Similarly, the integration of blood mQTL data (n = 1,980) with the same AD GWAS data identified 676 CpG sites ( $P_{SMR-multi}$  < 0.05,  $P_{HEIDI}$  > 0.05) (S5 Table). Further analysis combining the putative causal signals from the first two steps resulted in the identification of 6 CpG sites associated with the expression of two genes: PARL and BCL2L1 ( $P_{SMR-multi}$  < 0.05,  $P_{HEIDI}$  > 0.05) (S6 Table). In a similar manner, leveraging eQTL (n = 2,865) and mQTL (n = 1,160) data from brain tissues along with the same AD GWAS summary statistics, we identified 9 mitophagy-related genes and 83 CpG sites (P<sub>SMR-multi</sub> <0.05, P<sub>HFIDI</sub> >0.05) (S7 and S8 Table). By combining findings from

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

transcriptome and methylome data, the third analysis filtered out 7 CpG sites that putatively regulate the expression of three genes: ATG13, TOMM22, and SPATA33 (PSMR-multi < 0.05, PHEIDI >0.05) (S9 Table). The integration of multi-omics data from blood and brain tissues provides evidence supporting the causal relationships between mitophagy-related gene expression and AD pathogenesis, as shown in Table 1.

Table 1. Associations of mitophagy-related gene expression with AD identified through threestep SMR analysis

Analysis Type	Gene	Top SNP <sup>a</sup>	$P_{SMR-multi}$	$P_{ ext{ t HEIDI}}$	nsnp	betaSMR
					HEIDI	
Blood-based	PARL	rs7644746	$4.69 \times 10^{-3}$	0.18	20	-0.13
analysis	BCL2L1	rs6088962	$5.04 \times 10^{-3}$	0.11	20	0.41
Brain tissue analysis	ATG13	rs756343	$1.94 \times 10^{-2}$	0.15	20	0.03
	TOMM22	rs926299	$2.89 \times 10^{-2}$	0.61	20	0.05
	SPATA33	rs258334	$1.81 \times 10^{-3}$	0.10	20	-0.05

AD, Alzheimer's disease; SMR, summary-based Mendelian randomization; SNP, single nucleotide polymorphism;  $P_{SMR-multi}$ , p value from multi-SNP-based SMR method;  $P_{HEIDI}$ , pvalue from HEIDI test (Heterogeneity in Dependent Instruments); nsnp HEIDI: The number of SNPs used in the HEIDI test; beta<sub>SMR</sub>, effect size from SMR analysis. <sup>a</sup> Top SNP refers to the most significantly associated SNP with gene expression within a ciseQTL region and it is used to estimate the effect of gene expression on trait.

Plausible epigenetic regulation of mitophagy-related genes by DNA methylation in AD

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

The three-step SMR analysis gave us an opportunity to speculate on the genetic regulation model of mitophagy-related genes in AD. One illustrative case is the PARL gene, which encodes a serine rhomboid protease located in the mitochondrial intermembrane space and is involved in regulating mitophagy by mediating the cleavage of PINK1 and PGAM5 [52, 53]. DNAm site cg22921096 in the 5' untranslated region, 453 kbp downstream of PARL, was identified in the integration analysis of mQTL and AD GWAS summary statistics. The methylation level of this site exerted a positive effect on PARL expression (beta<sub>SMR</sub> = 0.07) and a negative effect on AD (beta<sub>SMR</sub> = -0.03). In addition, the PARL expression level was inversely related to the disease onset (beta<sub>SMR</sub> = -0.13). Collectively, these results suggest that higher methylation level at this site upregulates the transcript level of PARL, potentially offering a protective effect against AD risk (Fig 3A). ATG13, a key component of the ULK1 complex, is integral to the initiation of autophagy and mitophagy. Our analysis revealed a positive causal correlation between the ATG13 expression and DNAm site cg05585544, 957 kbp downstream of ATG13 (beta<sub>SMR</sub> = 0.13). The elevated expression of ATG13 gene (beta<sub>SMR</sub> = 0.03) and methylation levels of this CpG site (beta<sub>SMR</sub> = 0.05) potentially increased the susceptibility to AD. Therefore, it is hypothesized that the genetic variation modulates the DNAm status at this CpG site, leading to upregulation of ATG13 expression, which could contribute to a heightened risk of AD (Fig 3B). Fig 3. Three-step SMR analyses using molecular traits from blood and brain tissues. SMR tools were used to prioritize the mitophagy-related genes potentially causally associated with AD, along with relevant epigenetic mechanisms of genetic regulation (all P<sub>SMR-multi</sub> < 0.05, P<sub>HEIDI</sub> > 0.05). The panels, from left to right, depict the following analysis results: SMR between gene

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

expression and AD GWAS on the left, SMR between gene methylation and AD GWAS in the middle, and SMR between gene methylation and gene expression. Panels A and B present the respective results for the genes PARL and ATG13. eQTL, expression quantitative trait loci; GWAS, Genome-wide association studies; mQTL, DNA methylation quantitative trait loci External replication of mitophagy-related DEGs in AD GWAS summary statistics from UK Biobank For external replication, we made use of AD GWAS data from the UK Biobank (n=361,141) and integrated them with eQTLs and mQTLs of previously detected genes to validate our primary findings. All tested genes and relevant DNAm sites showed significant associations with AD in the UK Biobank cohort, thereby reinforcing the validity of our primary research results (S10 Table). Discussion This is the first study to identify mitophagy-related genes and their corresponding methylation sites potentially causally linked to AD. Dysregulation of mitophagy results in the buildup of defective mitochondria, which contribute to progression of AD pathologies such as AB aggregation, tau protein abnormalities, and neuroinflammation [5]. Targeting mitophagy has emerged as a promising therapeutic strategy, with animal model studies demonstrating its effectiveness in counteracting these pathological features and clinically improving cognitive deficits [54]. Since mitophagy-related DEGs in AD may either be a cause or an outcome of neurodegenerative processes [5, 55], it is essential to clarify the roles of these genes in AD development and their interactions with other biomolecules from a genetic perspective. By incorporating multi-omics data from different tissues through the SMR

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

method, we identified a potentially causal relationship between five mitophagy-related genes and AD, and investigated their genetic regulatory mechanisms via epigenomic modifications. Among the genes filtered out by the three-step SMR, most of them have been characterized in AD field. For instance, PARL, a susceptibility locus for AD, regulates mitophagy through the PINK1-Parkin pathway [56]. A recent genome-wide survival study and gene analysis have reported that the downregulation of PARL expression correlated with worsening clinical symptoms of AD [57]. Lower PARL expression has been shown to increase p-tau levels in different AD models, while overexpression of PARL reduced this accumulation in basic experiment [57]. Our study further identified the CpG methylation in the 5' untranslated region increased transcript level of PARL, potentially promoting its protective effect against AD (beta<sub>SMR</sub> = -0.13). Elevated levels of Bcl-xL have been observed in the brain tissues of AD patients [58]. The BCL2L1 gene encodes the Bcl-xL protein, an anti-apoptotic member of the Bcl-2 family, which modulates both apoptotic pathways and autophagy process, including mitophagy. Specifically, Bcl-xL inhibits mitophagy by binding to the BH3-like domain of Beclin 1, a key protein in the initiation and regulation of the process [59]. The inhibitory interaction between Beclin 1 and Bcl-xL could suppress activity of Beclin 1, thereby impairing mitophagy and exacerbating AD pathology [60]. ATG13, a vital component of the autophagy machinery, also plays an essential role in mitophagy processes [61]. At the onset of mitophagy, ATG13 forms the ULK complex with ULK1/2, ATG101 and FIP200, and the ULK complex initiates mitophagy by facilitating the formation and maturation of mitophagosomes [62], a structure that engulfs damaged

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

mitochondria and delivers them to lysosomes for degradation. Another significant finding from the three-step SMR analysis in brain tissue is the identification of TOMM22, a critical receptor within the translocase of the outer mitochondrial membrane (TOMM) complex, responsible for importing Parkin into mitochondria under normal conditions [63]. Previous studies have demonstrated that the destabilization of TOMM22 and TOMM40 acts as the switch to trigger the mitophagy [64]. Moreover, overexpression of TOMM22 partially inhibits Parkin-mediated mitochondrial clearance, suggesting that the proper regulation of TOMM22 is important for maintaining mitochondrial quality control [64]. Interestingly, SPATA33, identified as an autophagy mediator by recent experimental study, promotes the mitophagy in the male germline cells during spermatogenesis by interacting with the outer mitochondrial membrane protein VDAC2 and the autophagy-related protein ATG16L1 [65, 66]. The brain tissue analysis has suggested SPATA33 as a novel candidate gene potentially linked to AD development, although research in this area remains limited. The strength of our investigation lies in the integration of multi-omics data from multiple tissues, providing a comprehensive analysis of the causal associations between mitophagyrelated genes and AD. The three-step SMR with a more stringent statistical filtering criteria provided us stronger evidence to support our inference and enhanced our understanding of the genetic regulation mechanism involved in AD. Finally, all prioritized genes from the primary analysis were replicated in the other datasets, which further supported the reliability of the findings. This study has some limitations that are worth acknowledging. First, eQTLs change in response to different cell states and environmental conditions [67]. Second, this study focused

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

exclusively on cis-eQTLs and cis-mQTLs. Third, the participants included in these datasets were individuals of European ancestry, and the lack of ancestral diversity limits the applicability of our findings to more ethnically diverse populations. Conclusions In conclusion, our study emphasized the potential causal links between mitophagy-related genes and AD. We identified biological mechanisms where DNA methylation modifications modulates the expression of specific mitophagy-related genes, thereby influencing the onset and progression of AD. These insights offer a deeper understanding of the pathogenesis of AD and hold significant implications for the development of novel therapeutic targets. Supporting information S1 Table. Characteristics of 5 microarray datasets. S2 Table. 167 mitophagy-related genes list. S3 Table. Meta-analysis of 111 differentially expressed genes related to mitophagy from five datasets (p < 0.05). Estimate, combined effect size estimate; SE, standard error of the effect size estimate; Cl.lb, lower bound of the 95% confidence interval; Cl.ub, upper bound of the 95% confidence interval. S4 Table. Summary-based Mendelian randomization (SMR) analysis from blood gene expression to AD (all P<sub>SMR-multi</sub> < 0.05, P<sub>HEIDI</sub> > 0.05). ID, identifier; Chr, chromosome; bp, base pair position; SNP, single nucleotide polymorphisms; A1, effect (coded) allele; A2, other allele; Freq, frequency of effect allele; b, effect size; GWAS, Genome-Wide Association Studies; se, standard error; p, p-value; eQTL, expression quantitative trait locus; SMR, summary-based Mendelian randomization; SMR-multi, multi-SNP-based SMR; HEIDI, Heterogeneity in

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

Dependent Instruments test; nsnp HEIDI, number of SNPs used in the HEIDI test. S5 Table. SMR analysis from blood DNA methylation to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ). SMR, summary-based Mendelian randomization. S6 Table. SMR analysis from blood DNA methylation to gene expression (all  $P_{SMR-multi}$  < 0.05, PHEIDI > 0.05). Expo, exposure; ID, identifier; Chr, chromosome; bp: base pair position; Outco; outcome; A1: effect allele; A2: other allele; Freq: frequency of the effect allele (A1); b: effect size; se: standard error; p, p value; SMR, summary-based Mendelian randomization; SMRmulti, multi-SNP-based SMR; HEIDI, Heterogeneity in Dependent Instruments test; nsnp HEIDI, number of SNPs used in the HEIDI test. S7 Table. SMR analysis from brain gene expression to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ). S8 Table. SMR analysis from brain DNA methylation to AD (all  $P_{SMR-multi}$  < 0.05,  $P_{HFIDI}$  > 0.05). S9 Table. SMR analysis from brain DNA methylation to gene expression (all  $P_{SMR-multi}$  < 0.05,  $P_{HEIDI} > 0.05$ ). S10 Table. External validation of the UK Biobank database **Acknowledgments** We thank all participants and investigators of the GWAS Catalog and UK Biobank. **Author Contributions** Conceptualization: Weijian Zhang, Wenjia Chen, Hui Li. Data curation: Weijian Zhang, Zhendong Guo. Formal analysis: Weijian Zhang, Wenjia Chen. Methodology: Weijian Zhang, Zhendong Guo. Software: Weijian Zhang, Zhendong Guo.

- 303 Validation: Zhendong Guo.
- 304 Visualization: Weijian Zhang.
- Writing original draft: Weijian Zhang, Wenjia Chen, Zhendong Guo.
- 306 Writing review & editing: Weijian Zhang.
- 307 Funding acquisition: Hui Li.

#### 308 Reference

- 309 1. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer's Disease: Epidemiology and
- 310 Clinical Progression. Neurol Ther. 2022;11(2):553-69. Epub 20220314. doi: 10.1007/s40120-022-00338-
- 311 8. PubMed PMID: 35286590; PubMed Central PMCID: PMC9095793.
- 312 2. Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's
- disease and Parkinson's disease. Neurosci Biobehav Rev. 2019;103:73-80. Epub 20190614. doi:
- 314 10.1016/j.neubiorev.2019.06.018. PubMed PMID: 31207254; PubMed Central PMCID: PMC6700747.
- 315 3. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Ramos-Campo DJ, Belinchón-deMiguel
- P, Martinez-Guardado I, et al. Mitochondria and Brain Disease: A Comprehensive Review of Pathological
- 317 Mechanisms and Therapeutic Opportunities. Biomedicines. 2023;11(9). Epub 20230907. doi:
- 318 10.3390/biomedicines11092488. PubMed PMID: 37760929; PubMed Central PMCID: PMC10526226.
- 4. Yang X, Zhang Y, Luo J-x, Zhu T, Ran Z, Mu B-R, et al. Targeting mitophagy for neurological disorders
- 320 treatment: advances in drugs and non-drug approaches. Naunyn-Schmiedeberg's Archives of
- 321 Pharmacology. 2023;396(12):3503-28. doi: 10.1007/s00210-023-02636-w.
- 322 5. Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer's disease: Molecular defects and
- 323 therapeutic approaches. Mol Psychiatry. 2023;28(1):202-16. doi: 10.1038/s41380-022-01631-6.
- 324 6. Magalhães JD, Fão L, Vilaça R, Cardoso SM, Rego AC. Macroautophagy and Mitophagy in
- 325 Neurodegenerative Disorders: Focus on Therapeutic Interventions. Biomedicines. 2021;9(11). Epub
- 326 20211105. doi: 10.3390/biomedicines9111625. PubMed PMID: 34829854; PubMed Central PMCID:
- 327 PMC8615936.
- 328 7. Sukhorukov V, Voronkov D, Baranich T, Mudzhiri N, Magnaeva A, Illarioshkin S. Impaired
- 329 Mitophagy in Neurons and Glial Cells during Aging and Age-Related Disorders. Int J Mol Sci. 2021;22(19).
- 330 Epub 20210923. doi: 10.3390/ijms221910251. PubMed PMID: 34638589; PubMed Central PMCID:
- 331 PMC8508639.
- 332 8. Sharma B, Pal D, Sharma U, Kumar A. Mitophagy: An Emergence of New Player in Alzheimer's
- 333 Disease. Front Mol Neurosci. 2022;15:921908. Epub 20220706. doi: 10.3389/fnmol.2022.921908.
- PubMed PMID: 35875669; PubMed Central PMCID: PMC9296849.
- 9. Martín-Maestro P, Gargini R, García E, Perry G, Avila J, García-Escudero V. Slower Dynamics and
- 336 Aged Mitochondria in Sporadic Alzheimer's Disease. Oxid Med Cell Longev. 2017;2017:9302761. Epub
- 337 20171019. doi: 10.1155/2017/9302761. PubMed PMID: 29201274; PubMed Central PMCID:
- 338 PMC5672147.
- 339 10. Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, et al.
- 340 Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure,

- function, and mitophagy defects in Alzheimer's disease models and human brains. Acta Neuropathol.
- 342 2021;141(1):39-65. Epub 20201020. doi: 10.1007/s00401-020-02234-7. PubMed PMID: 33079262;
- 343 PubMed Central PMCID: PMC7785558.
- 344 11. Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and
- 345 tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci.
- 346 2019;22(3):401-12. Epub 20190211. doi: 10.1038/s41593-018-0332-9. PubMed PMID: 30742114;
- PubMed Central PMCID: PMC6693625.
- 348 12. Zhou T-Y, Ma R-X, Li J, Zou B, Yang H, Ma R-Y, et al. Review of PINK1-Parkin-mediated
- 349 mitochondrial autophagy in Alzheimer's disease. Eur J Pharmacol. 2023;959:176057. doi:
- 350 https://doi.org/10.1016/j.ejphar.2023.176057.
- 351 13. Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, et al. PINK1 signalling rescues amyloid pathology and
- 352 mitochondrial dysfunction in Alzheimer's disease. Brain. 2017;140(12):3233-51. doi:
- 353 10.1093/brain/awx258. PubMed PMID: 29077793; PubMed Central PMCID: PMC5841141.
- 354 14. Ono M, Komatsu M, Ji B, Takado Y, Shimojo M, Minamihisamatsu T, et al. Central role for
- 355 p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. Aging Cell.
- 356 2022;21(7):e13615. Epub 20220605. doi: 10.1111/acel.13615. PubMed PMID: 35662390; PubMed
- 357 Central PMCID: PMC9282839.
- 358 15. Wang XJ, Qi L, Cheng YF, Ji XF, Chi TY, Liu P, et al. PINK1 overexpression prevents forskolin-induced
- tau hyperphosphorylation and oxidative stress in a rat model of Alzheimer's disease. Acta Pharmacol
- 360 Sin. 2022;43(8):1916-27. Epub 20211210. doi: 10.1038/s41401-021-00810-5. PubMed PMID: 34893682;
- PubMed Central PMCID: PMC9343460.
- 362 16. Maity S, Farrell K, Navabpour S, Narayanan SN, Jarome TJ. Epigenetic Mechanisms in Memory and
- 363 Cognitive Decline Associated with Aging and Alzheimer's Disease. Int J Mol Sci. 2021;22(22). Epub
- 364 20211113. doi: 10.3390/ijms222212280. PubMed PMID: 34830163; PubMed Central PMCID:
- 365 PMC8618067.
- 366 17. Cadena-del-Castillo C, Valdes-Quezada C, Carmona-Aldana F, Arias C, Bermúdez-Rattoni F,
- 367 Recillas-Targa F. Age-dependent increment of hydroxymethylation in the brain cortex in the triple-
- transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2014;41(3):845-54. doi: 10.3233/jad-
- 369 132285. PubMed PMID: 24685633.
- 370 18. Shu L, Sun W, Li L, Xu Z, Lin L, Xie P, et al. Genome-wide alteration of 5-hydroxymenthylcytosine
- in a mouse model of Alzheimer's disease. BMC Genomics. 2016;17:381. Epub 20160520. doi:
- 372 10.1186/s12864-016-2731-1. PubMed PMID: 27207465; PubMed Central PMCID: PMC4875608.
- 373 19. De Plano LM, Saitta A, Oddo S, Caccamo A. Epigenetic Changes in Alzheimer's Disease: DNA
- Methylation and Histone Modification. Cells. 2024;13(8). Epub 20240421. doi: 10.3390/cells13080719.
- PubMed PMID: 38667333; PubMed Central PMCID: PMC11049073.
- 376 20. Monti N, Cavallaro RA, Stoccoro A, Nicolia V, Scarpa S, Kovacs GG, et al. CpG and non-CpG
- 377 Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated
- with gene expression in human and murine brain. Epigenetics. 2020;15(8):781-99. Epub 20200205. doi:
- 379 10.1080/15592294.2020.1722917. PubMed PMID: 32019393; PubMed Central PMCID: PMC7518704.
- 380 21. Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Julita MF, Yang J, et al. Rescue of Early bace-1 and
- 381 Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves
- 382 Cognition in an Alzheimer's Model. Sci Rep. 2016;6:34051. Epub 20160929. doi: 10.1038/srep34051.
- PubMed PMID: 27681803; PubMed Central PMCID: PMC5041108.

- 384 22. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide
- association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet.
- 386 2021;53(9):1276-82. Epub 20210907. doi: 10.1038/s41588-021-00921-z. PubMed PMID: 34493870;
- 387 PubMed Central PMCID: PMC10243600.
- 388 23. Brabec JL, Lara MK, Tyler AL, Mahoney JM. System-level analysis of Alzheimer's disease prioritizes
- candidate genes for neurodegeneration. Frontiers in Genetics. 2021;12:625246.
- 390 24. Sen A, Kalvakuri S, Bodmer R, Cox RT. Clueless, a protein required for mitochondrial function,
- interacts with the PINK1-Parkin complex in Drosophila. Dis Model Mech. 2015;8(6):577-89. Epub
- 392 20150420. doi: 10.1242/dmm.019208. PubMed PMID: 26035866; PubMed Central PMCID:
- 393 PMC4457034.
- 394 25. Migliore L, Coppede F. Gene-environment interactions in Alzheimer disease: the emerging role of
- 395 epigenetics. Nat Rev Neurol. 2022;18(11):643-60. Epub 20220930. doi: 10.1038/s41582-022-00714-w.
- 396 PubMed PMID: 36180553.
- 397 26. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG methylation in
- 398 sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Hum Mol Genet.
- 399 2014;23(3):648-56. Epub 20130918. doi: 10.1093/hmg/ddt451. PubMed PMID: 24101602.
- 400 27. Li QS, Sun Y, Wang T. Epigenome-wide association study of Alzheimer's disease replicates 22
- 401 differentially methylated positions and 30 differentially methylated regions. Clin Epigenetics.
- 402 2020;12(1):149. Epub 20201017. doi: 10.1186/s13148-020-00944-z. PubMed PMID: 33069246;
- 403 PubMed Central PMCID: PMC7568396.
- 404 28. Lin X, Barton S, Holbrook JD. How to make DNA methylome wide association studies more
- 405 powerful. Epigenomics. 2016;8(8):1117-29. Epub 20160407. doi: 10.2217/epi-2016-0017. PubMed
- 406 PMID: 27052998; PubMed Central PMCID: PMC5066141.
- 407 29. Young AS. Genome-wide association studies have problems due to confounding: Are family-based
- 408 designs the answer? PLoS Biol. 2024;22(4):e3002568. Epub 20240412. doi:
- 409 10.1371/journal.pbio.3002568. PubMed PMID: 38607978; PubMed Central PMCID: PMC11014432.
- 410 30. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from
- 411 GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481-7. Epub
- 412 20160328. doi: 10.1038/ng.3538. PubMed PMID: 27019110.
- 413 31. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol
- 414 Neurodegener. 2019;14(1):32. doi: 10.1186/s13024-019-0333-5.
- 415 32. Hokama M, Oka S, Leon J, Ninomiya T, Honda H, Sasaki K, et al. Altered expression of diabetes-
- related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex. 2014;24(9):2476-88.
- 417 Epub 20130417. doi: 10.1093/cercor/bht101. PubMed PMID: 23595620; PubMed Central PMCID:
- 418 PMC4128707.
- 419 33. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in
- 420 the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A. 2008;105(40):15605-
- 421 10. Epub 20081001. doi: 10.1073/pnas.0806883105. PubMed PMID: 18832152; PubMed Central PMCID:
- 422 PMC2563070.
- 423 34. Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW. Synaptic genes are
- 424 extensively downregulated across multiple brain regions in normal human aging and Alzheimer's
- 425 disease. Neurobiol Aging. 2013;34(6):1653-61. Epub 20121227. doi:
- 426 10.1016/j.neurobiolaging.2012.11.024. PubMed PMID: 23273601; PubMed Central PMCID:
- 427 PMC4022280.

- 428 35. Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate
- 429 immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and
- 430 neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179. Epub 20120723. doi:
- 431 10.1186/1742-2094-9-179. PubMed PMID: 22824372; PubMed Central PMCID: PMC3419089.
- 432 36. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis
- 433 of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One.
- 434 2010;5(9):e12538. Epub 20100908. doi: 10.1371/journal.pone.0012538. PubMed PMID: 20838618;
- 435 PubMed Central PMCID: PMC2935886.
- 436 37. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine SN, et al. Accelerated
- 437 neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest.
- 438 2013;123(10):4158-69. Epub 20130903. doi: 10.1172/jci69003. PubMed PMID: 23999428; PubMed
- 439 Central PMCID: PMC3784538.
- 440 38. Sárvári M, Hrabovszky E, Kalló I, Solymosi N, Likó I, Berchtold N, et al. Menopause leads to elevated
- 441 expression of macrophage-associated genes in the aging frontal cortex: rat and human studies identify
- 442 strikingly similar changes. J Neuroinflammation. 2012;9:264. Epub 20121203. doi: 10.1186/1742-2094-
- 443 9-264. PubMed PMID: 23206327; PubMed Central PMCID: PMC3558453.
- 444 39. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, et al. Gene expression profiles
- in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics.
- 446 2007;28(3):311-22. Epub 20061031. doi: 10.1152/physiolgenomics.00208.2006. PubMed PMID:
- 447 17077275; PubMed Central PMCID: PMC2259385.
- 448 40. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is
- associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc
- 450 Natl Acad Sci U S A. 2008;105(11):4441-6. Epub 20080310. doi: 10.1073/pnas.0709259105. PubMed
- 451 PMID: 18332434; PubMed Central PMCID: PMC2393743.
- 452 41. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. Multiscale
- 453 Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical
- 454 Networks by Human Herpesvirus. Neuron. 2018;99(1):64-82.e7. Epub 20180621. doi:
- 455 10.1016/j.neuron.2018.05.023. PubMed PMID: 29937276; PubMed Central PMCID: PMC6551233.
- 456 42. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, et al. Altered neuronal gene
- expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol
- 458 Genomics. 2008;33(2):240-56. Epub 20080212. doi: 10.1152/physiolgenomics.00242.2007. PubMed
- 459 PMID: 18270320; PubMed Central PMCID: PMC2826117.
- 460 43. McKay EC, Beck JS, Khoo SK, Dykema KJ, Cottingham SL, Winn ME, et al. Peri-Infarct Upregulation
- 461 of the Oxytocin Receptor in Vascular Dementia. J Neuropathol Exp Neurol. 2019;78(5):436-52. doi:
- 462 10.1093/jnen/nlz023. PubMed PMID: 30990880; PubMed Central PMCID: PMC6467199.
- 463 44. Piras IS, Krate J, Delvaux E, Nolz J, Mastroeni DF, Persico AM, et al. Transcriptome Changes in the
- 464 Alzheimer's Disease Middle Temporal Gyrus: Importance of RNA Metabolism and Mitochondria-
- 465 Associated Membrane Genes. J Alzheimers Dis. 2019;70(3):691-713. doi: 10.3233/jad-181113. PubMed
- 466 PMID: 31256118.
- 467 45. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into
- 468 the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022;54(4):412-36. Epub
- 469 20220404. doi: 10.1038/s41588-022-01024-z. PubMed PMID: 35379992; PubMed Central PMCID:
- 470 PMC9005347.
- 471 46. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-

- 472 eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene
- 473 expression. Nat Genet. 2021;53(9):1300-10. Epub 20210902. doi: 10.1038/s41588-021-00913-z.
- 474 PubMed PMID: 34475573; PubMed Central PMCID: PMC8432599.
- 475 47. Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, et al. Integrative analysis of omics summary data
- 476 reveals putative mechanisms underlying complex traits. Nat Commun. 2018;9(1):918. Epub 20180302.
- 477 doi: 10.1038/s41467-018-03371-0. PubMed PMID: 29500431; PubMed Central PMCID: PMC5834629.
- 478 48. Qi T, Wu Y, Fang H, Zhang F, Liu S, Zeng J, et al. Genetic control of RNA splicing and its distinct role
- 479 in complex trait variation. Nat Genet. 2022;54(9):1355-63. doi: 10.1038/s41588-022-01154-4.
- 480 49. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related traits
- 481 using transcriptomic and methylomic data from blood. Nature Communications. 2018;9(1):2282. doi:
- 482 10.1038/s41467-018-04558-1.
- 483 50. Viechtbauer W. Conducting Meta-Analyses in R with The metafor Package. Journal of Statistical
- 484 Software. 2010;36. doi: 10.18637/jss.v036.i03.
- 485 51. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for
- 486 human genetic variation. Nature. 2015;526(7571):68-74. doi: 10.1038/nature15393. PubMed PMID:
- 487 26432245; PubMed Central PMCID: PMC4750478.
- 488 52. Sekine S, Kanamaru Y, Koike M, Nishihara A, Okada M, Kinoshita H, et al. Rhomboid protease PARL
- mediates the mitochondrial membrane potential loss-induced cleavage of PGAM5. J Biol Chem.
- 490 2012;287(41):34635-45. Epub 20120822. doi: 10.1074/jbc.M112.357509. PubMed PMID: 22915595;
- 491 PubMed Central PMCID: PMC3464569.
- 492 53. Lysyk L, Brassard R, Touret N, Lemieux MJ. PARL Protease: A Glimpse at Intramembrane
- 493 Proteolysis in the Inner Mitochondrial Membrane. J Mol Biol. 2020;432(18):5052-62. Epub 20200419.
- 494 doi: 10.1016/j.jmb.2020.04.006. PubMed PMID: 32320686.
- 495 54. Yang X, Zhang Y, Luo JX, Zhu T, Ran Z, Mu BR, et al. Targeting mitophagy for neurological disorders
- 496 treatment: advances in drugs and non-drug approaches. Naunyn Schmiedebergs Arch Pharmacol.
- 497 2023;396(12):3503-28. Epub 20230803. doi: 10.1007/s00210-023-02636-w. PubMed PMID: 37535076.
- 498 55. Jiménez-Loygorri JI, Boya P. Aging STINGs: mitophagy at the crossroads of neuroinflammation.
- 499 Autophagy. 2024;20(7):1684-6. Epub 20240306. doi: 10.1080/15548627.2024.2322421. PubMed PMID:
- 38411192; PubMed Central PMCID: PMC11210893.
- 501 56. Shi G, McQuibban GA. The Mitochondrial Rhomboid Protease PARL Is Regulated by PDK2 to
- Integrate Mitochondrial Quality Control and Metabolism. Cell Rep. 2017;18(6):1458-72. doi:
- 503 10.1016/j.celrep.2017.01.029. PubMed PMID: 28178523.
- 504 57. Chen SD, Zhang W, Feng YW, Wu BS, Yang L, Zhang YR, et al. Genome-wide Survival Study Identifies
- 505 PARL as a Novel Locus for Clinical Progression and Neurodegeneration in Alzheimer's Disease. Biol
- 506 Psychiatry. 2023;94(9):732-42. Epub 20230303. doi: 10.1016/j.biopsych.2023.02.992. PubMed PMID:
- 507 36870520.
- 508 58. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of
- proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain
- 510 Res. 1998;780(2):260-9. doi: 10.1016/s0006-8993(97)01202-x. PubMed PMID: 9507158.
- 511 59. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell
- 512 Death Differ. 2011;18(4):571-80. Epub 20110211. doi: 10.1038/cdd.2010.191. PubMed PMID:
- 513 21311563; PubMed Central PMCID: PMC3131912.
- 514 60. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, et al. Impaired
- autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. Prog

- 516 Neurobiol. 2013;106-107:33-54. Epub 20130701. doi: 10.1016/j.pneurobio.2013.06.002. PubMed 517 PMID: 23827971.
- 518 61. Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, et al. Hsp90-Cdc37
- 519 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011;43(4):572-85. doi:
- 520 10.1016/j.molcel.2011.06.018. PubMed PMID: 21855797; PubMed Central PMCID: PMC3485687.
- 521 62. Fujita K, Kedashiro S, Yagi T, Hisamoto N, Matsumoto K, Hanafusa H. The ULK complex-LRRK1 axis
- regulates Parkin-mediated mitophagy via Rab7 Ser-72 phosphorylation. J Cell Sci. 2022;135(23). Epub
- 523 20221207. doi: 10.1242/jcs.260395. PubMed PMID: 36408770; PubMed Central PMCID: PMC9789397.
- 524 63. Pitt AS, Buchanan SK. A Biochemical and Structural Understanding of TOM Complex Interactions
- and Implications for Human Health and Disease. Cells. 2021;10(5). Epub 20210511. doi:
- 526 10.3390/cells10051164. PubMed PMID: 34064787; PubMed Central PMCID: PMC8150904.
- 527 64. Bertolin G, Ferrando-Miguel R, Jacoupy M, Traver S, Grenier K, Greene AW, et al. The TOMM
- machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance.
- 529 Autophagy. 2013;9(11):1801-17. Epub 20130905. doi: 10.4161/auto.25884. PubMed PMID: 24149440.
- 530 65. Xu X, Zhang Y, Cheng H, Zhou R. SPATA33 functions as a mitophagy receptor in mammalian
- 531 germline. Autophagy. 2021;17(5):1284-6. Epub 20210405. doi: 10.1080/15548627.2021.1909836.
- PubMed PMID: 33818286; PubMed Central PMCID: PMC8143240.
- 533 66. Zhang Y, Xu X, Hu M, Wang X, Cheng H, Zhou R. SPATA33 is an autophagy mediator for cargo
- 534 selectivity in germline mitophagy. Cell Death Differ. 2021;28(3):1076-90. Epub 20201021. doi:
- 535 10.1038/s41418-020-00638-2. PubMed PMID: 33087875; PubMed Central PMCID: PMC7937689.
- 536 67. van der Wijst MGP, Brugge H, de Vries DH, Deelen P, Swertz MA, Franke L. Single-cell RNA
- sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. Nat Genet. 2018;50(4):493-7.
- 538 Epub 20180402. doi: 10.1038/s41588-018-0089-9. PubMed PMID: 29610479; PubMed Central PMCID:
- 539 PMC5905669.

540

541




Fig 2. Volcano plot of differentially expressed genes related to m




Fig 3A. SMR between DNA methylation and AD (in the middle)

## ENSG00000175193 (PARL)




Fig 3A. SMR between PARL gene expression and AD (on the left)




Fig 3A. SMR between DNA methylation and PARL gene expressio

## ENSG00000175224.16 (ATG13)




Fig 3B. SMR between ATG13 and AD (on the left)




Fig 3B. SMR between DNA methylation and AD (in the middle)




Fig 3B. SMR between DNA methylation and ATG13 (on the right)




Fig 1. Flowchart of the study.